{"title":"[A Case of Hepatocellular Carcinoma with Simultaneous Bone Metastasis Successfully Treated with Multidisciplinary Therapy].","authors":"Toshihiko Goto, Susumu Sawada, Kunpei Ishida, Rina Ko, Yuta Iwasaki, Nozomu Nakanishi, Koshiro Morino, Norihiro Shimoike, Hirokazu Tanaka, Ryo Matsusue, Michihiro Yamamoto, Takafumi Machimoto","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The patient was a 52-year-old male, who, after experiencing lower back pain, underwent further investigation and was diagnosed with hepatocellular carcinoma with sacral metastasis. The hepatocellular carcinoma was a 9 cm tumor with a risk of rupture. Liver resection was performed, and lenvatinib was initiated at a dose of 4 mg/day postoperatively. Radical radiation therapy was then administered to address bone metastases. Lenvatinib was discontinued after 15 months due to skin disorders. Seven months have passed since the discontinuation of lenvatinib and 2 years since surgery. The patient's condition has progressed without any recurrence.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 12","pages":"1243-1245"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The patient was a 52-year-old male, who, after experiencing lower back pain, underwent further investigation and was diagnosed with hepatocellular carcinoma with sacral metastasis. The hepatocellular carcinoma was a 9 cm tumor with a risk of rupture. Liver resection was performed, and lenvatinib was initiated at a dose of 4 mg/day postoperatively. Radical radiation therapy was then administered to address bone metastases. Lenvatinib was discontinued after 15 months due to skin disorders. Seven months have passed since the discontinuation of lenvatinib and 2 years since surgery. The patient's condition has progressed without any recurrence.